JP6990583B2 - 鼻腔内投与 - Google Patents

鼻腔内投与 Download PDF

Info

Publication number
JP6990583B2
JP6990583B2 JP2017526959A JP2017526959A JP6990583B2 JP 6990583 B2 JP6990583 B2 JP 6990583B2 JP 2017526959 A JP2017526959 A JP 2017526959A JP 2017526959 A JP2017526959 A JP 2017526959A JP 6990583 B2 JP6990583 B2 JP 6990583B2
Authority
JP
Japan
Prior art keywords
oxytocin
optionally
nasal
expanded
supply device
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017526959A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017538478A5 (enExample
JP2017538478A (ja
Inventor
ギスレ ジュペスランド，パー
エイ マハムード，ラミー
エイ アンドレアセン，オーレ
ティー ウェストレー，ラース
エス キンタナ，ダニエル
ティー スメラド，クヌート
デービット シェルドレイク，コリン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Optinose AS
Original Assignee
Optinose AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Optinose AS filed Critical Optinose AS
Publication of JP2017538478A publication Critical patent/JP2017538478A/ja
Publication of JP2017538478A5 publication Critical patent/JP2017538478A5/ja
Application granted granted Critical
Publication of JP6990583B2 publication Critical patent/JP6990583B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M31/00—Devices for introducing or retaining media, e.g. remedies, in cavities of the body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/08—Inhaling devices inserted into the nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/095—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0001—Details of inhalators; Constructional features thereof
    • A61M15/0013—Details of inhalators; Constructional features thereof with inhalation check valves
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0001—Details of inhalators; Constructional features thereof
    • A61M15/0021—Mouthpieces therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/009—Inhalators using medicine packages with incorporated spraying means, e.g. aerosol cans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0091—Inhalators mechanically breath-triggered
    • A61M15/0098—Activated by exhalation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M29/00—Dilators with or without means for introducing media, e.g. remedies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/04—Liquids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/06—Solids
    • A61M2202/064—Powder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2210/00—Anatomical parts of the body
    • A61M2210/06—Head
    • A61M2210/0618—Nose

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Anesthesiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Otolaryngology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
JP2017526959A 2014-11-19 2015-11-19 鼻腔内投与 Active JP6990583B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462081742P 2014-11-19 2014-11-19
US62/081,742 2014-11-19
PCT/EP2015/077162 WO2016079267A1 (en) 2014-11-19 2015-11-19 Intranasal administration

Publications (3)

Publication Number Publication Date
JP2017538478A JP2017538478A (ja) 2017-12-28
JP2017538478A5 JP2017538478A5 (enExample) 2018-12-20
JP6990583B2 true JP6990583B2 (ja) 2022-01-12

Family

ID=54695714

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017526959A Active JP6990583B2 (ja) 2014-11-19 2015-11-19 鼻腔内投与
JP2017526941A Active JP6937690B2 (ja) 2014-11-19 2015-11-19 鼻腔内投与

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2017526941A Active JP6937690B2 (ja) 2014-11-19 2015-11-19 鼻腔内投与

Country Status (19)

Country Link
US (6) US11052204B2 (enExample)
EP (3) EP3733235B1 (enExample)
JP (2) JP6990583B2 (enExample)
KR (2) KR20170086599A (enExample)
CN (3) CN111921046B (enExample)
AU (2) AU2015348297A1 (enExample)
BR (2) BR112017010522B1 (enExample)
CA (2) CA2966802C (enExample)
DK (2) DK3220988T3 (enExample)
ES (3) ES2906984T3 (enExample)
HK (1) HK1244729A1 (enExample)
IL (2) IL251935A0 (enExample)
MX (2) MX2017006265A (enExample)
MY (1) MY188242A (enExample)
PL (1) PL3220989T3 (enExample)
RU (2) RU2714168C2 (enExample)
SG (2) SG11201703792XA (enExample)
WO (2) WO2016079271A1 (enExample)
ZA (1) ZA201704149B (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0311570D0 (en) 2003-05-20 2003-06-25 Optinose As Delivery device and method
GB0320171D0 (en) 2003-08-28 2003-10-01 Optinose As Delivery devices
GB0420513D0 (en) 2004-09-15 2004-10-20 Optinose As Powder delivery devices
GB0503738D0 (en) 2005-02-23 2005-03-30 Optinose As Powder delivery devices
GB0604444D0 (en) * 2006-03-06 2006-04-12 Optinose As Nasal devices
GB0605799D0 (en) 2006-03-23 2006-05-03 Optinose As Nasal delivery devices
GB2438834A (en) 2006-06-08 2007-12-12 Optinose As Intranasal protein administration
GB2440316A (en) 2006-07-25 2008-01-30 Optinose As Nasal inhaler with scrubber
GB0623731D0 (en) 2006-11-28 2007-01-10 Optinose As Delivery device
GB0623732D0 (en) 2006-11-28 2007-01-10 Optinose As Powder delivery devices
GB0623728D0 (en) 2006-11-28 2007-01-10 Optinose As Delivery devices
GB2448193A (en) 2007-04-05 2008-10-08 Optinose As Nasal delivery device
GB2448183A (en) 2007-04-05 2008-10-08 Optinose As Nasal powder delivery device
GB0719299D0 (en) 2007-10-03 2007-11-14 Optinose As Nasal delivery devices
US9949923B2 (en) 2011-03-15 2018-04-24 Optinose As Nasal delivery
SG10201600092UA (en) 2012-02-24 2016-02-26 Optinose As Nasal Delivery Devices
USD761951S1 (en) 2013-05-23 2016-07-19 Optinose As Nosepiece unit
JP6990583B2 (ja) 2014-11-19 2022-01-12 オプティノーズ アズ 鼻腔内投与
US10368502B2 (en) 2017-09-25 2019-08-06 Multiple Energy Technologies Llc Bioceramic and carbon-based hydroponic systems, methods and devices
JP2021520266A (ja) 2018-04-12 2021-08-19 ロケット サイエンス ヘルス コープ． 鼻腔内薬剤送達デバイス、システム、およびプロセス
KR102148613B1 (ko) * 2019-01-28 2020-10-14 닉스 주식회사 이산화탄소를 이용한 수면 유도시스템
CN110188836B (zh) * 2019-06-21 2021-06-11 西安交通大学 一种基于变分自编码器的脑功能网络分类方法
US20220313895A1 (en) * 2019-08-14 2022-10-06 Gsk Consumer Healthcare Sarl Bi-material nozzle for nasal washes
US11241477B2 (en) 2019-08-29 2022-02-08 New York University Oxytocin compositions for treatment of tinnitus
US20220161000A1 (en) * 2020-11-24 2022-05-26 Medtronic, Inc. Multi-durometer attachment device for chronic fixation
CN112972879A (zh) * 2021-04-20 2021-06-18 苏州新劢德医疗器械科技有限公司 流体分配设备
CN112999499A (zh) * 2021-04-20 2021-06-22 苏州新劢德医疗器械科技有限公司 流体分配设备
CN114306207A (zh) * 2021-12-30 2022-04-12 电子科技大学 一种以棒棒糖为载体的口腔给药方法
US20230285278A1 (en) * 2022-03-06 2023-09-14 Optinose, Inc. Methods for treating chronic rhinosinusitis
WO2025118074A1 (en) * 2023-12-04 2025-06-12 Rocket Science Health Corp. Olfactory delivery of therapeutic peptides
WO2025174892A1 (en) * 2024-02-13 2025-08-21 Breathewave Technologies Inc. Personalized-fit nasal dilator

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007528248A (ja) 2004-03-11 2007-10-11 グラクソ　グループ　リミテッド 流体放出装置
US20100282246A1 (en) 2007-04-05 2010-11-11 Optinose As Nasal delivery
JP2011511674A (ja) 2008-02-07 2011-04-14 ユニヴァーシティ オブ ワシントン 周方向エアロゾルデバイス
US20140073562A1 (en) 2011-03-15 2014-03-13 Optinose As Nasal delivery

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US605436A (en) 1898-06-07 Inhaler
US642748A (en) 1899-02-23 1900-02-06 Arthur Manners Inhaler.
US658436A (en) 1900-05-28 1900-09-25 Hans Hennerich Groth Insufflator.
US746749A (en) 1903-03-18 1903-12-15 George E Seidel Nasal medicator.
US794641A (en) 1905-03-06 1905-07-11 Alfred H Ramey Inhaler.
US902832A (en) 1907-09-20 1908-11-03 Edward F Philbrook Inhaler.
KR100390480B1 (ko) 1995-01-23 2003-10-04 디렉트-할러 아/에스 흡입기
US5901703A (en) 1995-02-06 1999-05-11 Unisia Jecs Corporation Medicine administering device for nasal cavities
JP3320288B2 (ja) * 1995-11-15 2002-09-03 株式会社ユニシアジェックス 鼻腔用投薬器
US5797392C1 (en) 1996-01-22 2001-01-09 Direct Haler As Inhaler
US6648848B1 (en) 1997-05-27 2003-11-18 Direct-Haler A/S Inhaler for powdered medicaments
GB9719775D0 (en) 1997-09-18 1997-11-19 Glaxo Group Ltd Device
FR2771296B1 (fr) * 1997-11-25 2000-03-10 Sofab Embout nasal avec fermeture d'extremite
GB0114272D0 (en) 2001-06-12 2001-08-01 Optinose As Nasal delivery device
BR0008650B1 (pt) 1999-03-03 2010-12-28 dispositivo de transmissão via nasal.
GB0121568D0 (en) 2001-09-06 2001-10-24 Optinose As Nasal delivery device
US20070032410A1 (en) 2000-01-11 2007-02-08 Atossa Healthcare, Inc. Compositions and methods for the treatment of psychiatric disorders
US6894026B1 (en) 2000-01-11 2005-05-17 Atossa Healthcare, Inc. Long-acting oxytocin analogues for the treatment and prevention of breast cancer and psychiatric disorders
GB0015309D0 (en) 2000-06-21 2000-08-16 Djupesland Per G Apparatus
ZA200306564B (en) 2001-02-26 2004-10-15 Optinose As Nasal devices.
GB0207422D0 (en) 2002-03-28 2002-05-08 Optinose As Nasal devices
GB0207817D0 (en) 2002-04-04 2002-05-15 Optinose As Nasal devices
GB0209494D0 (en) 2002-04-25 2002-06-05 Optinose As Nasal devices
GB0215270D0 (en) 2002-07-02 2002-08-14 Optinose As Nasal devices
GB0215904D0 (en) 2002-07-09 2002-08-21 Team Holdings Uk Ltd Drug delivery system and method
GB0300008D0 (en) 2003-01-02 2003-02-05 Optinose As Delivery devices
GB2400565B (en) 2003-04-17 2005-03-02 Bespak Plc Nasal drug delivery
GB0311570D0 (en) 2003-05-20 2003-06-25 Optinose As Delivery device and method
GB0319119D0 (en) 2003-08-14 2003-09-17 Optinose As Delivery devices
GB0320171D0 (en) 2003-08-28 2003-10-01 Optinose As Delivery devices
USD530815S1 (en) 2004-03-19 2006-10-24 Optinose As Nasal delivery device
GB0420513D0 (en) 2004-09-15 2004-10-20 Optinose As Powder delivery devices
GB0503738D0 (en) 2005-02-23 2005-03-30 Optinose As Powder delivery devices
EP1928484B1 (en) 2005-08-26 2010-02-24 The Board Of Trustees Of The Leland Stanford Junior University Methods for treatment of headaches by administration of oxytocin
JP4765526B2 (ja) 2005-10-04 2011-09-07 オムロンヘルスケア株式会社 吸入器および吸入器用マウスピース
EP1984049A1 (en) 2006-01-19 2008-10-29 Optinose AS Nasal administration
EP1988953B1 (en) 2006-02-14 2017-07-19 Optinose AS Delivery device
GB0602980D0 (en) 2006-02-14 2006-03-29 Optinose As Delivery device and method
GB0604319D0 (en) 2006-03-03 2006-04-12 Optinose As Nasal delivery
GB0604444D0 (en) * 2006-03-06 2006-04-12 Optinose As Nasal devices
GB0605799D0 (en) 2006-03-23 2006-05-03 Optinose As Nasal delivery devices
GB2437488A (en) 2006-04-25 2007-10-31 Optinose As Pharmaceutical oily formulation for nasal or buccal administration
GB2438834A (en) 2006-06-08 2007-12-12 Optinose As Intranasal protein administration
GB2440316A (en) 2006-07-25 2008-01-30 Optinose As Nasal inhaler with scrubber
JP2008062974A (ja) * 2006-09-07 2008-03-21 Mitani Valve Co Ltd 内容物放出用容器ならびに、この内容物放出用容器を備えたポンプ式製品およびエアゾール式製品
GB0623731D0 (en) 2006-11-28 2007-01-10 Optinose As Delivery device
GB0623728D0 (en) 2006-11-28 2007-01-10 Optinose As Delivery devices
GB0623732D0 (en) 2006-11-28 2007-01-10 Optinose As Powder delivery devices
US20100199984A1 (en) 2007-04-02 2010-08-12 Abbott Laboratories Breath actuated nasal pump
GB2448183A (en) 2007-04-05 2008-10-08 Optinose As Nasal powder delivery device
US8342173B2 (en) 2007-07-19 2013-01-01 Silver Eagle Labs Inc. Nasal dilator with cushion layer and variable spring rate
GB0719299D0 (en) * 2007-10-03 2007-11-14 Optinose As Nasal delivery devices
EP2242526A4 (en) 2008-02-15 2014-06-18 Timothy Sean Immel AEROSOL TREATMENT DEVICE WITH HIGH FREQUENCY ADMINISTRATION
US20110318345A1 (en) 2008-09-15 2011-12-29 Optinose As Nasal delivery
GB201015371D0 (en) 2010-09-14 2010-10-27 Optinose As Nasal delivery
GB201020638D0 (en) * 2010-12-06 2011-01-19 Liconsa Laboratorios Sa Inhalator
RU112044U1 (ru) * 2011-08-25 2012-01-10 Наиль Минрахманович Нуртдинов Тренажер-ингалятор
SG10201600092UA (en) 2012-02-24 2016-02-26 Optinose As Nasal Delivery Devices
JP6382723B2 (ja) 2012-02-24 2018-08-29 オプティノーズ アズ 経鼻配送装置
JP6286367B2 (ja) 2012-02-24 2018-02-28 オプティノーズ アズ 経鼻配送装置
BR112015024869A8 (pt) * 2013-03-26 2019-12-17 Optinose As uso de um agente terapêutico e/ou de diôxido de carbono para tratar um paciente e aparelhos e métodos para tratar terapeuticamente um paciente
US11554229B2 (en) 2013-03-26 2023-01-17 OptiNose Inc. Nasal administration
USD761951S1 (en) 2013-05-23 2016-07-19 Optinose As Nosepiece unit
USD725769S1 (en) 2013-05-23 2015-03-31 Optinose As Nasal delivery device
USD723156S1 (en) 2013-05-23 2015-02-24 Optinose As Nasal delivery device
JP6990583B2 (ja) 2014-11-19 2022-01-12 オプティノーズ アズ 鼻腔内投与
US20220296825A1 (en) 2018-10-04 2022-09-22 Optinose As Exhalation delivery system for and method of treating sinus disease

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007528248A (ja) 2004-03-11 2007-10-11 グラクソ　グループ　リミテッド 流体放出装置
US20100282246A1 (en) 2007-04-05 2010-11-11 Optinose As Nasal delivery
JP2011511674A (ja) 2008-02-07 2011-04-14 ユニヴァーシティ オブ ワシントン 周方向エアロゾルデバイス
US20140073562A1 (en) 2011-03-15 2014-03-13 Optinose As Nasal delivery

Also Published As

Publication number Publication date
CA2966797A1 (en) 2016-05-26
AU2015348297A1 (en) 2017-05-25
US11707586B2 (en) 2023-07-25
MY188242A (en) 2021-11-24
CA2966797C (en) 2023-06-27
ES2949052T3 (es) 2023-09-25
JP2017538477A (ja) 2017-12-28
US20210322690A1 (en) 2021-10-21
HK1244729A1 (zh) 2018-08-17
DK3220988T3 (da) 2022-02-14
US20250114543A1 (en) 2025-04-10
WO2016079267A1 (en) 2016-05-26
BR112017010522B1 (pt) 2022-08-02
AU2015348301B2 (en) 2020-09-03
US20160331916A1 (en) 2016-11-17
CN107106792A (zh) 2017-08-29
CN111921046A (zh) 2020-11-13
US20160310683A1 (en) 2016-10-27
IL251935A0 (en) 2017-06-29
EP3220989A1 (en) 2017-09-27
JP6937690B2 (ja) 2021-09-22
ES2906984T3 (es) 2022-04-21
CN106999684A (zh) 2017-08-01
US20210275761A1 (en) 2021-09-09
EP3733235C0 (en) 2023-06-14
SG11201703792XA (en) 2017-06-29
EP3220989B1 (en) 2020-06-24
KR20170086599A (ko) 2017-07-26
PL3220989T3 (pl) 2021-03-22
EP3220988B1 (en) 2022-01-12
MX2017006265A (es) 2017-08-14
MX2017006268A (es) 2017-08-14
CN107106792B (zh) 2020-08-18
RU2714168C2 (ru) 2020-02-12
EP3733235A1 (en) 2020-11-04
RU2017114951A3 (enExample) 2019-04-16
IL251936A0 (en) 2017-06-29
WO2016079271A1 (en) 2016-05-26
EP3220988A1 (en) 2017-09-27
KR20170085121A (ko) 2017-07-21
CN111921046B (zh) 2022-07-22
BR112017010561A2 (pt) 2017-12-26
IL251936B (en) 2020-07-30
US20230372647A1 (en) 2023-11-23
ZA201704149B (en) 2019-12-18
US11052204B2 (en) 2021-07-06
SG11201703794TA (en) 2017-06-29
EP3733235B1 (en) 2023-06-14
CA2966802C (en) 2022-11-15
BR112017010522A2 (pt) 2017-12-26
DK3220989T3 (da) 2020-08-24
JP2017538478A (ja) 2017-12-28
US11730904B2 (en) 2023-08-22
AU2015348301A1 (en) 2017-05-25
RU2017114951A (ru) 2018-12-19
CA2966802A1 (en) 2016-05-26
MX383241B (es) 2025-03-13
ES2813442T3 (es) 2021-03-23
CN106999684B (zh) 2021-03-09
HK1244728A1 (en) 2018-08-17
US10940277B2 (en) 2021-03-09
RU2017114950A (ru) 2018-12-19

Similar Documents

Publication Publication Date Title
JP6990583B2 (ja) 鼻腔内投与
Anagnostou et al. Intranasal oxytocin in the treatment of autism spectrum disorders: a review of literature and early safety and efficacy data in youth
HK40033122A (en) Intranasal administration
Pirnia et al. An experimental single-case design in effectiveness of oxytocin on reducing alcohol addiction in a patient with oropharyngeal carcinoma-the mediation role of difficulties in emotional regulation
HK1244728B (en) Intranasal administration
Li et al. Foot massage evokes oxytocin release and activation of
Sluijs-Veer et al. Quality of life, developmental milestones, and self-esteem of young adults with congenital hypothyroidism diagnosed by neonatal screening.
Fischer Functional Connectivity of Brain Reward Circuitry in Patients with Schizophrenia and Cannabis Use Disorder: Effects of Cannabis and Delta-9-Tetrahydrocannabinol (THC)

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171124

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181112

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20181112

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20190930

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20191015

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200107

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200414

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20201006

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20201228

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210304

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210817

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211104

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20211130

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20211206

R150 Certificate of patent or registration of utility model

Ref document number: 6990583

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250